Recent progress in ankylosing spondylitis treatment

Bibliography

• WOLLHEIM FA: Ankylosing spondylitis. In: Textbook of Rheumatology Kelley WN, Harris ED, Ruddy S (Ed.), Saunders, Phidadelphia USA (1993):943–955.
   Google Scholar
• VAN DER LINDEN S, VAN DER HEIDJE D: Ankylosing spondylitis. Clinical features. Rheum. Dis. Clin. N Am. (1998) 24(4):663–676.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38(4):499–505.
   PubMed Web of Science ®Google Scholar
• •A study demonstrating the presence of T cells, macrophages and TNF-a mRNA in the sacroiliac joints of AS patients.
   Google Scholar
• LALOUX L, VOISIN MC, ALLAIN J et al.: Immunohistological study of entheses in spondylarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. (2001) 60(4):316–321.
   PubMedGoogle Scholar
• BAETEN D, DEMETTER P, CUVELIER C et al.: Comparative study of the synovial histology in rheumatoid arthritis, spondylarthropathy, and osteoarthritis: influence of disease duration and activity. Ann. Rheum. Dis. (2000) 59(12):945–953.
   PubMedGoogle Scholar
• BROWN MA, KENNEDY LG, MACGREGOR At et al.: Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. (1997) 40(10):1823–1828.
   PubMed Web of Science ®Google Scholar
• ALLEN RL, O'CALLAGHAN CA, MCMICHAEL AJ, BOWNES P: Cutting edge: HLA-B27 can form a novel 132-microglobulin free heavy chain homodimer structure. J. Immunol (1999) 162(9):5045–5048.
   PubMedGoogle Scholar
• CALIN A: Terminology, introduction, diagnostic criteria, and overview. In: The Spondylarthritides. Calm A, Taurog JD (Eds) Oxford University Press, Oxford UK (1998):1–15.
   Google Scholar
• BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. (1998) 41:58–67.
   PubMed Web of Science ®Google Scholar
• SARAUX A, GUEDES C, ALLAIN J et al: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Rheumatol (1999) 26(12):2622–2627.
   Google Scholar
• BALL EJ, KHAN MA: HLA-B27 polymorphism. Joint Bone Spine (2001) 68(5):378–382.
   PubMedGoogle Scholar
• LITTLE H: The natural history of ankylosing spondylitis. Rheumatol (1988) 15(8):1179–1180.
   Google Scholar
• CALIN A, ELSWOOD J, RIGG S et al.: Ankylosing spondylitis: an analytical review of 1500 patients. The changing pattern of the disease. J. Rheumatol (1988) 15(8):1234–1238.
   PubMedGoogle Scholar
• GRAN JT, SKOMSVOLL JF: The outcome of ankylosing spondylitis: a study of 100 patients. Br. J. Rheumatol (1997) 36(7):766–771.
   PubMedGoogle Scholar
• AMOR B, SANTOS RS, NAHAL R, LISTRAT V, DOUGADOS M: Predictive factors for the longterm outcome of spondylarthropathies. Rheumatol (1994) 21(10):1883–1887.
   Web of Science ®Google Scholar
• KHAN MA, KHAN MK, KUSHNER I: Survival among patients with ankylosing spondylitis: a life-table analysis. Rheumatol (1981) 8(1):86–90.
   Google Scholar
• ROUSSOU E, KENNEDY LG, GARRETT S, CALIN A: Socioeconomic status in ankylosing spondylitis: relationship between occupation and disease ativity. Rheumatol (1997) 24(5):908–911.
   Web of Science ®Google Scholar
• BOONEN A, CHORUS A, MIEDEMA H, VAN DER HEIJDE D, VAN DER TAMPLE H, VAN DER LINDEN SJ: Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann. Rheum. Dis. (2001) 60(4):353–358.
   PubMed Web of Science ®Google Scholar
• •A cross-sectional study showing the impact of AS on work status.
   Google Scholar
• GRAN JT, HUSBY G: Ankylosing spondylitis. Current drug treatment. Drugs (1992) 44(4):585–603.
   PubMed Web of Science ®Google Scholar
• ••A literature review of pharmacotherapy inAS, especially the use of NSAIDs.
   Google Scholar
• GARRETT S, JENKINSON T, WHITELOCK H et al.: A new approach to defining disease status in AS: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) .1 Rheumatol (1994) 21(12):2286–2291.
   Google Scholar
• CALIN A, GARRETT S, WHITELOCK H et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index (BASET). Rheumatul (1994) 21(12):2281–2285.
   PubMed Web of Science ®Google Scholar
• ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritic Rheum. (2001) 44(8):1876–1886.
   PubMed Web of Science ®Google Scholar
• •A proposition for criteria of symptomatic improvement in AS.
   Google Scholar
• BRAUN J, BOLLOW M, EGGENS U et al.: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritic Rheum. (1994) 37(7):1039–1045.
   PubMedGoogle Scholar
• D'AGOSTINO MA, BREBAN M, SAID-NAHAL R, DOUGADOS M: Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritic Rheum. (2002) 46(3):840–841.
   PubMed Web of Science ®Google Scholar
• CALIN A, ELSWOOD J: A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. Rheumatul (1990) 17(6):801–803.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E, WENDLING D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs (1998) 56(2):225–240.
   PubMed Web of Science ®Google Scholar
• ••A recent literature review of the drugtreatment in AS, including the second-line treatments.
   Google Scholar
• LAURENT R: Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? Baillere's Clin. Rheumatul (1990) 4(2):387–400.
   Google Scholar
• CREEMERS MCW, VAN RIEL PCLM, FRANSSEN MJAM: Second-line treatment in seronegative spondylarthropathies. Semin. Arthritis Rheum. (1994) 24(2):71–81.
   PubMed Web of Science ®Google Scholar
• BOSI-FERRAZ M, TUGWELL P, GOLDSMITH C et al.: Meta-analysis of sulfasalazine in ankylosing spondylitis. Rheumatul (1990) 17(11):1782–1786. ••A meta-analysis of the use and efficacy ofsulfasalazine in AS.
   Google Scholar
• DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al: Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double blind, placebo-controlled study. Arthritic Rheum. (1995) 38(5):618–627.
   PubMedGoogle Scholar
• CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and periperal articular manifestations of seronegative spondylarthropathies. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1999) 42(11):2325–2329.
   PubMed Web of Science ®Google Scholar
• •A study of the differential effects of sulfasalazine on axial and peripheral manifestations of spondylarthropathies based upon the analysis of a large, controlled, randomised trial involving 619 patients.
   Google Scholar
• MAUGARS Y, MATHIS C, BERTHELOT JM et al.: Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double blind study. Br. J. Rheumatul (1996) 35(8):767–770.
   PubMedGoogle Scholar
• VAN TUBERGEN A, LANDEWE R, VAN DER HEIDJE D et al.: Combined spa-exercise is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritic Rheum. (2001) 45(5):403–408.
   Google Scholar
• GRATACOS J, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNFoc, IL-10 and TENy) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatul (1994) 33(10):927–931.
   PubMedGoogle Scholar
• MIELANTS H, VEYS EM: HLA-B27 related arthritis and bowel inflammation: sulfasalazine in HLA-B27 related arthritis. Rheumatul (1985) 12(2):287–293.
   PubMedGoogle Scholar
• SANDBORN WJ: Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm. Bowel Dis. (1999) 5(2):119–133.
   PubMed Web of Science ®Google Scholar
• BRAUN J, DE KEYSER F, BRANDT J, MIEALNTS H, SIEPER J, VEYS E: New treatment option in spondylarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Can: Opin. Rheumatul (2001) 13(4):245–249.
   PubMedGoogle Scholar
• SIEPER J, BRAUN J: New treatment options in ankylosing spondylitis: a role for anti-TNEa therapy. Ann. Rheum. Dis. (2001) 60 (Suppl. 3):ili58–61.
   Google Scholar
• VAN DEN BOSCH, BAETEN D, KRUITHOF E, DE KEYSER F, MIELANTS H, VEYS EM: Treatment of active spondylarthropathy with infliximab, the chimeric monoclonal antibody to tumor necrosis factor a. Ann. Rheum. Dis. (2001) 60\(Suppl. 3):iii33–66.
   Google Scholar
• MARKHAM A, LAMB HM: Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs (2000) 59(6):1341–1359.
   Google Scholar
• Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR001, Enbrel. Drugs Res. Dev. (1999) 1(3):258–261.
   Google Scholar
• BRANDT J, HAIBEL H, CORNELY D et al: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritic Rheum. (2000) 43(6):1346–1352.
   PubMed Web of Science ®Google Scholar
• ••The first study that reported the dramaticimprovement of AS patients with refractory and severe disease with the monoclonal antibody infliximab.
   Google Scholar
• VAN DER BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) in spondylarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59(6):428–433.
   PubMed Web of Science ®Google Scholar
• ••A second open study with infliximabconfirming the results of [42] and extending the treatment to the other spondylarthropathies (psoriatic arthritis and undifferenciated spondylarthropathy).
   Google Scholar
• MARZO-ORTEGA H, MCGONALE D, O'CONNOR D et al: Efficacy of etanercept in the treatment of entheseal pathology in resistant spondylarthropathy. A clinical and magnetic resonance imaging study. Arthritic Rheum. (2001) 44(9):2112–2117.
   Google Scholar
• STONE M, SALONEN D, LAX M et al: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. I Rheumatul (2001) 28(7):1605–1614.
   PubMed Web of Science ®Google Scholar
• •A study showing the imaging amelioration of synovitis with infliximab treatment.
   Google Scholar
• KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: Repeated infusions of infliximab, a chimeric anti-TNEcc monoclonal antibody in patients with active spondylarthropathy: one year follow up. Ann. Rheum. Dis. (2002) 61(3):207–212.
   Google Scholar
• MAKSYMOWYCH W, JHANGRI GS, LAMBERT RG et al.: Infliximab in ankylosing spondylitis: a prospective bservational inception cohort analalysis of efficacy and safety. Rheumatul. (2002) 29(5)959–965.
   Google Scholar
• VAN DEN BOSCH, KRUITHOF E, BAETEN D et al.: Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondylarthropathy. Arthritic Rheum. (2002) 46(3):755–765.
   PubMedGoogle Scholar
• ••The first placebo controlled trialconfirming the strong efficacy of infliximab in spondylarthropathy.
   Google Scholar
• BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet (2002) 359(6):1187–1193.
   PubMedGoogle Scholar
• GORMAN J, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N. Eng]. J. Med. (2002) 346(18):1349–1356.
   PubMed Web of Science ®Google Scholar
• BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Immunomodulatory effects of anti-tumor necrosis factor a therapy on synovium in spondylarthropathy. Arthritic Rheum. (2001) 44(1):186–195.
   Google Scholar
• BAETEN D, VAN DAMME N, VAN DEN BOSCH F et al.: Impaired Thl cytokine production in spondylarthropathy is restored by anti-TNF a. Ann. Rheum. Dis. (2001) 60(8):750–755.
   Google Scholar
• BRANDT J, LISTING J, ALTEN R et al.: One year results of a double blind placebo controlled, phase III clinical trial of infliximab in active ankylosing spondylitis. Ann. Rheum. Dis. (2002) 61\(Suppl. 1):292 (Abstract).
   Google Scholar
• DUNN CJ, GALINET LA, WU H et al: Demonstration of novel anti-arthritic and antiinflammatory effects of disphosphonates. Pharmacy]. Exp. Ther. (1993) 266(3):1691–1698.
   PubMedGoogle Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LECLERCQ S, SKEITH K, YAN A, RUSSEL AS: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. .1 Rheumatul. (1998) 25(4):714–717.
   Google Scholar
• ••The first open study of pamidronate in ASpatients giving favourable results on axial symptoms.
   Google Scholar
• MAKSYMOWYCH WP, LAMBERT R, JHANGRI GS et al: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J.Rheumatol. (2001) 28(1):144–155.
   PubMedGoogle Scholar
• MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA et al.: A six-month randomized, controlled, double-blind, dose response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritic Rheum. (2002) 46(3):766–773.
   PubMed Web of Science ®Google Scholar
• ••A comparative study showing the clinicaleffects of pamidronate in refractory AS patients.
   Google Scholar
• CREEMERS MCW, FRANSEN MJAM, VAN DE PUTTE LBA et al.: Methotrexate in severe ankylosing spondylitis: an open study. Rheumatul. (1995) 22(6):1104–1107.
   Google Scholar
• BIASI D, CARLETTO A, CAAMASCHI P, PACOR ML, MALEKNIA T, BAMBARA LM: Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin. Rheumatul. (2000) 19(2):114–117.
   PubMedGoogle Scholar
• •A recent, open study of methotrexate therapy in AS with a long-term follow-up.
   Google Scholar
• SAMPAIO-BARROS PD, COSTALLAT LTL, BERTOLO M et al.: Methotrexate in the treatment of ankylosing spondylitis. Scand. Rheumatul. (2000) 29(3):160–162.
   PubMedGoogle Scholar
• •Another recent open study of methotrexate therapy in AS giving contrasting results to [59].
   Google Scholar
• ALTAN L, BINGOL U, KARAKOC Y et al.: Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. Rheumatul. (2001) 30(5):255–259.
   PubMedGoogle Scholar
• BREBAN M, GOMBERT B, AMOR B, DOUGADOS M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritic Rheum. (1999) 42(3):580–581.
   PubMed Web of Science ®Google Scholar
• HUANG F, GU J, ZHAO W, ZHU J, ZHANG J, YAN YU DT: One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritic Rheum. (2002) 47(3):249–254.
   PubMedGoogle Scholar
• DOUGADOS M, BEHIERJ, JOLCHINE I et al.: Efficacy of celecoxib, a COX-2 specific inhibitor in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. (2001) 44(1):180–185.
   PubMedGoogle Scholar
• •The first study evaluating the effects and tolerability of a new anti-COX-2 selective agent - celecoxib.
   Google Scholar
• DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatalogy (1999) 38(3):235–244.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E, WENDLING D: Bone mass in ankylosing spondylitis. Clin. Exp. Rheumatul. (2000) 18\(Suppl. 21):S16–S20.
   Google Scholar
• KRUITHOF E, KESTELYN P, ELEWAUT C et al.: Successful use of infliximab in a patient with treatment resistant spondylarthropathy related uveitis. Ann. Rheum. Dis. (2002) 61(5):470.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J et al: Etanerept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356(9227):385–390.
   PubMed Web of Science ®Google Scholar
• ••A placebo-controlled trial demonstratingthe efficacy of etanercept on both skin and joint manifestations in psoriatic arthritis patients.
   Google Scholar